No abstract

Background: Sintilimab (Innovent Biologics, China, Suzhou, China) has been listed in China for only a year and a half. So far, there have been no reports about it in real research. The purpose of this study was to evaluate the efficacy and safety of the real-world use of Sintilimab in the treatment of recurrent or refractory lymphoma and to explore the factors that influence the efficacy and safety of Sintilimab. Methods: Based on real world data, a retrospective analysis of 25 patients with relapsed or refractory lymphoma treated with Sintilimab was performed.Results: Efficacy was evaluable in 19 of 25 patients, objective response rate (ORR), disease control rate (DCR) and clinical response rate (CBR) were 63.2%, 84.2% and 73.7%, respectively. Among the different pathological types, Hodgkin's lymphoma ORR 77.8%, CBR 100%, diffuse large B-cell lymphoma ORR 25%, CBR 0%, peripheral T/NK cell lymphoma ORR 66.7%, CBR 83.3%. The number of previous chemotherapy courses was correlated with the short-term efficacy of the patients (P=0.029). In the safety analysis, 76% of treatment-related adverse events occurred, 80% of which were grade 1 and 2, with the major adverse events being hypothyroidism and anemia. Hypothyroidism is related to sex.Conclusions: Sintilimab is effective in recurrent or refractory lymphoma and the adverse reactions are controllable. The fewer the lines of previous chemotherapies, the better the short-term efficacy of Sintilimab. The use of Sintilimab in female patients should be paid more attention to thyroid function.